Results 21 to 30 of about 39,591 (271)

Outcomes of Abrupt Switch to Bevacizumab of Patients Undergoing Aflibercept Intravitreal Injections for Neovascular Age-Related Macular Degeneration in a Tertiary Center in Lombardy, Italy: A Real-Life Retrospective Analysis

open access: yesJournal of Ophthalmology, 2021
Purpose. To assess real-life anatomical and functional outcomes of switch to bevacizumab in patients undergoing aflibercept intravitreal injections for nAMD. Methods.
Alessandro Randazzo   +8 more
doaj   +1 more source

Widening use of dexamethasone implant for the treatment of macular edema [PDF]

open access: yes, 2017
Sustained-release intravitreal 0.7 mg dexamethasone (DEX) implant is approved in Europe for the treatment of macular edema related to diabetic retinopathy, branch retinal vein occlusion, central retinal vein occlusion, and non-infectious uveitis.
Avitabile T.   +9 more
core   +2 more sources

Pharmacokinetics, Safety, and Efficacy of Intravitreal Digoxin in Preclinical Models for Retinoblastoma [PDF]

open access: yes, 2015
PURPOSE:To assess in vitro cytotoxic activity and antiangiogenic effect, ocular and systemic disposition, and toxicity of digoxin in rabbits after intravitreal injection as a potential candidate for retinoblastoma treatment.METHODS:A panel of two ...
Abramson, David   +13 more
core   +2 more sources

Acceptability of intravitreal injections in geographic atrophy: protocol for a mixed-methods pilot study

open access: yesBMJ Open, 2021
Introduction Age-related macular degeneration (AMD) is a common cause of visual impairment, affecting central vision. Geographic atrophy (GA) is an advanced form of the non-neovascular (dry) type of AMD.
David P Crabb   +4 more
doaj   +1 more source

Intravitreal injection of Ozurdex(®) implant in patients with persistent diabetic macular edema, with six-month follow-up [PDF]

open access: yes, 2016
AIM: To evaluate the efficacy of intravitreal dexamethasone injections in diabetic macular edema (DME). METHODS: A 700 μg slow-release intravitreal dexamethasone implant (Ozurdex®) was placed in the vitreal cavity of 17 patients (19 eyes) affected ...
Bottone, A   +8 more
core   +2 more sources

Long-Term Intravitreal Ranibizumab as a Potential Additional Risk Factor for Neurodegeneration in Parkinson's Disease: A Case Report. [PDF]

open access: yes, 2018
In November 2012, a 72-year old patient was diagnosed with left eye wet age-related macular degeneration. The patient received three monthly intravitreal injections of ranibizumab, with complete resolution of retinal hemorrhage and edema and ...
Antonini   +43 more
core   +2 more sources

Intravitreal injections, antibiotics and endophthalmitis [PDF]

open access: yesEye, 2013
Sir, The article by Lyall et al1 entitled ‘Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes' is timely, given current efforts to minimize the risk of endophthalmitis following intravitreal injections.
A R, Bhavsar, D R, Sandler, R C, Gentile
openaire   +2 more sources

Effect of Alternate Treatment with Intravitreal Corticosteroid and Anti-VEGF for Macular Edema Secondary to Retinal Vein Occlusion

open access: yesJournal of Ophthalmology, 2021
Purpose. To evaluate whether treatment with intravitreal corticosteroid and anti-vascular endothelial growth factor (VEGF) injections alternately can improve treatment outcomes of macular edema (ME) caused by retinal vein occlusion (RVO). Methods.
Young Hwan Bae   +5 more
doaj   +1 more source

Intravitreal Administration of Human Bone Marrow CD34+ Stem Cells in a Murine Model of Retinal Degeneration. [PDF]

open access: yes, 2016
PurposeIntravitreal murine lineage-negative bone marrow (BM) hematopoietic cells slow down retinal degeneration. Because human BM CD34+ hematopoietic cells are not precisely comparable to murine cells, this study examined the effect of intravitreal human
Annett, Geralyn   +10 more
core   +2 more sources

Morphologic Criteria of Lesion Activity in Neovascular Age-Related Macular Degeneration: A Consensus Article [PDF]

open access: yes, 2017
Intravitreal antivascular endothelial growth factor drugs represent the current standard of care for neovascular age-related macular degeneration (nAMD).
Elena Gusson   +8 more
core   +1 more source

Home - About - Disclaimer - Privacy